{"_links":{"self":[{"href":"/project/GID-TAG360"}]},"_embedded":{"nice.indev:topic-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:topic":[{"_links":{"self":[{}]},"ETag":null,"Item":"Cancer"},{"_links":{"self":[{}]},"ETag":null,"Item":"Digestive system"}]},"ETag":null},"nice.indev:provisional-schedule-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:provisional-schedule":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Closing date for invited submissions / evidence submission:","Column2":"<strong>TBC</strong>","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"1st appraisal committee meeting:","Column2":"<strong>TBC</strong>","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:timeline-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:timeline":[{"_links":{"self":[{}]},"ETag":null,"Column1":"22 July 2014","Column2":"We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib.","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"20 February 2014","Column2":"Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:process-homepage":{"_links":{"self":[{"href":"https://www.nice.org.uk/process/pmg20/chapter/introduction"},{}]},"ETag":null,"Description":"For further information on our processes and methods, please see our","LinkText":"CHTE processes and methods manual default"},"nice.indev:project-team-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:project-team":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Communications manager:","Column2":"<strong>Alice Law</strong>"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Project manager:","Column2":"<strong><p>Jeremy Powell</p>\n</strong>"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Technical Lead:","Column2":"<strong>Ahmed Elsada</strong>"}]},"ETag":null},"nice.indev:consultee-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:consultee":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Manufacturers/sponsors","Column2":"AB Science (masitinib)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Department of Health"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"NHS Leeds South and East CCG"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"NHS England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"NHS Telford &amp; Wrekin CCG"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Welsh Government"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Afiya Trust"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Beating Bowel Cancer"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Black Health Agency"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Bladder and Bowel Foundation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Bowel Cancer Information (formerly Lynn&#8217;s Bowel Cancer Campaign)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Bowel Cancer UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Cancer Black Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Cancer Equality"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Cancer52"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Equalities National Council"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"GIST Support UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Helen Rollason Cancer Charity"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Independent Cancer Patient&#8217;s Voice"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Macmillan Cancer Support"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Maggie&#8217;s Centres"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Marie Curie Cancer Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Muslim Council of Britain"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Muslim Health Network"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Ochre"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Oesophageal Patients Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Rarer Cancers Foundation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Sarcoma UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"South Asian Health Foundation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Specialised Healthcare Alliance"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient/carer groups","Column2":"Tenovus"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Association of Cancer Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Association of Surgeons of Great Britain and Ireland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Association for Services to the Elderly"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Association of Surgical Oncology"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Geriatric Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Institute of Radiology"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Psychosocial Oncology Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Society of Gastroenterology"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Cancer Network Pharmacists Forum"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Cancer Research UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of General Practitioners"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Nursing"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Pathologists"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Radiologists"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal Pharmaceutical Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal Society of Medicine"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Society and College of Radiographers"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"UK Health Forum"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"United Kingdom Clinical Pharmacy Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"United Kingdom Oncology Nursing Society"}]},"ETag":null},"nice.indev:commentator-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:commentator":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated Guideline Groups","Column2":"National Collaborating Centre for Cancer"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated Public Health Groups","Column2":"Public Health England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated Public Health Groups","Column2":"Public Health Wales NHS Trust"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator manufacturer(s)","Column2":"Pfizer (sunitinib)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Evidence Review Group","Column2":"Aberdeen HTA Group"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Evidence Review Group","Column2":"National Institute for Health Research Health Technology Assessment Programme"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Allied Health Professionals Federation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Board of Community Health Councils in Wales"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"British National Formulary"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Care Quality Commission"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Commissioning Support Appraisals Service"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Department of Health,Social Services and Public Safety for Northern Ireland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Healthcare Improvement Scotland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Medicines and Healthcare products Regulatory Agency"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"National Association of Primary Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"National Pharmacy Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"NHS Alliance"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"NHS Commercial Medicines Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"NHS Confederation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General","Column2":"Scottish Medicines Consortium"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Bowel &amp; Cancer Research"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Cochrane Upper Gastrointestinal and Pancreatic Diseases Group"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"CORE (Digestive Disorders Foundation)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Health Research Authority"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Institute of Cancer Research"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"MRC Clinical Trials Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"National Cancer Research Institute"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"National Cancer Research Network"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"National Institute for Health Research"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Research Institute for the Care of Older People"}]},"ETag":null},"nice.indev:panel-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:panel":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-equality-impact-assessment-scoping"}]},"ETag":null,"Id":"2d4wlgy4eqrvi4h6gmgtq3m35q","MimeType":"text/html","FileName":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-equality-impact-assessment-scoping","Length":2775,"Hash":"190B3FB062045A490925EDD8337527614BBF8273","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-equality-impact-assessment-scoping","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): equality impact assessment - scoping","Level":1,"PublishedDate":null,"ExternalUrl":null,"ShowInDocList":false,"TextOnly":true,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-equality-impact-assessment-scoping2"}]},"ETag":null,"Id":"ysnkz2at4xie3n66vqpdmys2bu","MimeType":"application/pdf","FileName":"65199.pdf","Length":66997,"Hash":"FCAA53043DA018E122BFBAA9E7EB5B9F673BC338","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-equality-impact-assessment-scoping2","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): equality impact assessment - scoping","Level":1,"PublishedDate":"2013-09-12T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): equality impact assessment - scoping","PanelType":"History","LegacyPanel":true,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-response-to-consultee-and-commentator-comments-on-the-draft-scope-and-provisional-matrix"}]},"ETag":null,"Id":"ffel23qpv7n6gwsc4elt4lk62a","MimeType":"text/html","FileName":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-response-to-consultee-and-commentator-comments-on-the-draft-scope-and-provisional-matrix","Length":3040,"Hash":"2A9EFB1DC31350EF75DE8749F60A56D627CC54BD","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-response-to-consultee-and-commentator-comments-on-the-draft-scope-and-provisional-matrix","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): response to consultee and commentator comments on the draft scope and provisional matrix","Level":1,"PublishedDate":null,"ExternalUrl":null,"ShowInDocList":false,"TextOnly":true,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-response-to-consultee-and-commentator-comments-on-the-draft-scope-and-provisional-matrix2"}]},"ETag":null,"Id":"ktinfx6bxpwc72xe5eziqfe45y","MimeType":"application/pdf","FileName":"65137.pdf","Length":248464,"Hash":"DD5FECBA1EF02004F821C7C683B33AD60912D269","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-response-to-consultee-and-commentator-comments-on-the-draft-scope-and-provisional-matrix2","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): response to consultee and commentator comments on the draft scope and provisional matrix","Level":1,"PublishedDate":"2013-09-04T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): response to consultee and commentator comments on the draft scope and provisional matrix","PanelType":"History","LegacyPanel":true,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-matrix"}]},"ETag":null,"Id":"r7oo7cx6byc432dc2hc4gn7g6y","MimeType":"text/html","FileName":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-matrix","Length":2659,"Hash":"0CE8E4FC5E18699CEBE7B95B926A1AAAC833B14C","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-matrix","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final matrix","Level":1,"PublishedDate":null,"ExternalUrl":null,"ShowInDocList":false,"TextOnly":true,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-matrix2"}]},"ETag":null,"Id":"qccskbwrcsla7usdmanuv2qpmu","MimeType":"application/pdf","FileName":"65136.pdf","Length":101533,"Hash":"EBC862A5BE1B0DEC47B496554F070E4B7FD6F4BA","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-matrix2","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final matrix","Level":1,"PublishedDate":"2013-09-04T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final matrix","PanelType":"History","LegacyPanel":true,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-scope"}]},"ETag":null,"Id":"bluifac37q6qyupf2fe42tdiiy","MimeType":"text/html","FileName":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-scope","Length":2654,"Hash":"272461EEE76E6DDA109EA8A30DDB87FBD1F74953","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-scope","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final scope","Level":1,"PublishedDate":null,"ExternalUrl":null,"ShowInDocList":false,"TextOnly":true,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-scope2"}]},"ETag":null,"Id":"i75o2i37mjbrosux4zwvuqrh6i","MimeType":"application/pdf","FileName":"65135.pdf","Length":97717,"Hash":"B8229D218043C0822FB45C2B3B8B797EEDD8038B","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-post-imatinib-final-scope2","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final scope","Level":1,"PublishedDate":"2013-09-04T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (post imatinib): final scope","PanelType":"History","LegacyPanel":true,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-provisional-matrix-prereferral"}]},"ETag":null,"Id":"yzmvsu5btr5rzecacconnixoqq","MimeType":"text/html","FileName":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-provisional-matrix-prereferral","Length":2838,"Hash":"8ED6391B45AF20573733E00B46B2FB7D1D2309E7","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-provisional-matrix-prereferral","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): provisional matrix (pre-referral)","Level":1,"PublishedDate":null,"ExternalUrl":null,"ShowInDocList":false,"TextOnly":true,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-provisional-matrix-prereferral2"}]},"ETag":null,"Id":"kwffzxzrepghyqpo2hnlbdcb2u","MimeType":"application/pdf","FileName":"64404.pdf","Length":98938,"Hash":"6254670B89234E047CBB80BBCCF982FBC5EF5207","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-provisional-matrix-prereferral2","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): provisional matrix (pre-referral)","Level":1,"PublishedDate":"2013-07-10T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): provisional matrix (pre-referral)","PanelType":"History","LegacyPanel":true,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-draft-scope-prereferral"}]},"ETag":null,"Id":"wivzqddtx7w6p63jmnn3l4ok7y","MimeType":"text/html","FileName":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-draft-scope-prereferral","Length":2804,"Hash":"0559CB9253466D0D7293C9D69113C1E35D8473E2","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-draft-scope-prereferral","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): draft scope (pre-referral)","Level":1,"PublishedDate":null,"ExternalUrl":null,"ShowInDocList":false,"TextOnly":true,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TAG360/documents/gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-draft-scope-prereferral2"}]},"ETag":null,"Id":"ohaq6pvvodw2v4ddnxluuh2q3y","MimeType":"application/pdf","FileName":"64403.pdf","Length":104564,"Hash":"6418777CA19ECE86CBFDD9E821B62C53FBE7799D","Name":"default","Reference":"GID-TAG360","ResourceTitleId":"gastrointestinal-stromal-tumours-unresectable-metastatic-masitinib-after-progression-with-imatinib-draft-scope-prereferral2","ConsultationDocumentId":0}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): draft scope (pre-referral)","Level":1,"PublishedDate":"2013-07-10T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib): draft scope (pre-referral)","PanelType":"History","LegacyPanel":true,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true}]},"ETag":null}},"ETag":"01000000-0000-0001-0000-000000000D3E","Summary":"Masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib","Description":"","ReferralDate":"","SuspendDiscontinuedReason":null,"SuspendDiscontinuedUrl":null,"SuspendDiscontinuedUrlText":null,"LegacyModel":true,"ProductReference":null,"EvidenceAssessmentGroup":null,"Reference":"GID-TAG360","ProjectType":"TA","TechnologyType":null,"ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-02-18T18:04:03","FirstGoLiveDate":null,"CreatedDate":"2015-02-18T18:04:03","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"AreasOfInterestList":[],"TopicSelectionDecision":"Selected","TopicSelectionReason":null,"TopicSelectionDecisionDate":null,"TopicSelectionFurtherInfo":null,"IndicatorSubTypes":[]}